Hemostasis Today

May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Read Jamie Madrigal, Dougald Monroe, Suzanne Sindi and Karin Leiderman’s Latest Analysis on Emicizumab
Oct 4, 2025, 10:23

Read Jamie Madrigal, Dougald Monroe, Suzanne Sindi and Karin Leiderman’s Latest Analysis on Emicizumab

Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn:

”Mathematical analysis of emicizumab: affinity-driven complex formation and lipid-surface reactions

This study used mathematical modeling and biochemical assays to dissect how emicizumab, a bispecific antibody bridging activated factor IXa and factor X, functions differently from factor VIII.

It revealed that high emicizumab levels inhibit factor X activation via tissue factor pathway due to reduced lipid surface binding but enhance factor IXa-dependent activation of factor X on lipid surfaces.

The model provides kinetic estimates and explains emicizumab’s mechanism of enhancing coagulation through lipid-surface interactions.

Read this paper.

Authors: Jamie Madrigal, Dougald Monroe, Suzanne Sindi, Karin Leiderman

Read the full article in JTH.

Article: Mathematical analysis of emicizumab: affinity-driven complex formation and lipid-surface reactions

Authors: Jamie Madrigal, Dougald Monroe, Suzanne Sindi, Karin Leiderman

Read Jamie Madrigal, Dougald Monroe, Suzanne Sindi and Karin Leiderman's Latest Analysis on Emicizumab

Stay updated on all scientific advances with Hemostasis Today.